Peptide record

TPDB27269

Antibacterial Anticancer Antifungal Antiparasitic Toxicity modified_plain modified
18 source-reported length (unverified)
Basic Information
TPDB27269
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CAFPdb dbAMP dbAMP 3.0
modified_plain
Yes
A modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide record curated from Peptipedia, CAFPdb, dbAMP, and other sources, without an available 3D structural model. Source-reported length: 18 (unverified).
Modified, details unspecified
Sequence
XCRRLCYKQRCVTYCRGR

Source notation is retained verbatim; residue notation and chemical identity have not been independently validated. The displayed length is source-reported and unverified.

Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
18 source-reported length (unverified)
Evidence Records 9 records
Evidence 1 Activity

Activity

4.4±0.1% Hemolysis
Toxicity
300 µg/mL
Hemolytic Cytotoxic
4.4±0.1% Hemolysis | 300 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Contribution of Amphipathicity and Hydrophobicity to the Antimicrobial Activity and Cytotoxicity of β-Hairpin Peptides. | ACS Infect Dis | 2016
Evidence 2 Activity

Activity

50% Cell death
Toxicity
49.9±16.6 µM
Cytotoxic
50% Cell death | 49.9±16.6 | µM | target cell: Human foreskin fibroblasts (HFF)

Target

Human foreskin fibroblasts (HFF)

Source & Reference

NA
DBAASP
Redesigned Spider Peptide with Improved Antimicrobial and Anticancer Properties. | ACS Chem Biol | 2017
Evidence 3 Activity

Activity

47.2±6.0% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
47.2±6.0% Hemolysis | 64 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigned Spider Peptide with Improved Antimicrobial and Anticancer Properties. | ACS Chem Biol | 2017
Evidence 4 Activity

Activity

50% Cell death
Toxicity
13.4±1.8 µM
Cytotoxic
50% Cell death | 13.4±1.8 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Redesigned Spider Peptide with Improved Antimicrobial and Anticancer Properties. | ACS Chem Biol | 2017
Evidence 5 Activity

Activity

50% Cell death
Toxicity
75 µg/mL
Cytotoxic
50% Cell death | 75 | µg/mL | target cell: Human neonatal skin fbroblasts NFF

Target

Human neonatal skin fbroblasts NFF

Source & Reference

NA
DBAASP
Gomesin inhibits melanoma growth by manipulating key signaling cascades that control cell death and proliferation. | Sci Rep | 2018
Evidence 6 Activity

Activity

18% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
18% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Gomesin inhibits melanoma growth by manipulating key signaling cascades that control cell death and proliferation. | Sci Rep | 2018
Evidence 7 Activity

Activity

16% Hemolysis
Toxicity
1 µM
Hemolytic Cytotoxic
16% Hemolysis | 1 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 8 Activity

Activity

CC50
Toxicity
58.2±3.0 µM
Cytotoxic
CC50 | 58.2±3.0 | µM | target cell: Human foreskin fibroblasts (HFF)

Target

Human foreskin fibroblasts (HFF)

Source & Reference

NA
DBAASP
Redesigned Spider Peptide with Improved Antimicrobial and Anticancer Properties. | ACS Chem Biol | 2017
Evidence 9 Activity

Activity

30.7±8.1% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
30.7±8.1% Hemolysis | 64 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigned Spider Peptide with Improved Antimicrobial and Anticancer Properties. | ACS Chem Biol | 2017